Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Options Exercise Instructions
    • Top 40 Shareholders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

ASX Announcements 2022

  • 30 May 2022

    Positive FDA Guidance for COVID-19 Clinical Program

  • 2 May 2022

    BIT225 Effective Against Established SARS-CoV-2 in Animals

  • 26 Apr 2022

    Report on Activities for the Quarter Ended 31 March 2022

  • 26 Apr 2022

    Quarterly Report 31 March 2022

  • 5 Apr 2022

    R&D Tax Incentive

  • 17 Mar 2022

    Confirmation of BIT225 Effectiveness Against COVID-19 in Animals

  • 23 Feb 2022

    Half-year Report 31 December 2021

  • 28 Jan 2022

    Report on Activities for the Quarter Ended 31 December 2021

  • 28 Jan 2022

    Quarterly Report 31 December 2021

 

 

 

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • >>

Investor Centre

  • Investor Centre
    • ASX Announcements
    • Annual reports
    • Corporate Directory
    • Shareholder services
    • Top 40 Shareholders
    • Corporate Governance
    • Corporate Presentations
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 30 May 2022        Legal Notices and Privacy